ARIA: Real-world Utilization and Outcomes With Dacomitinib First-line Treatment for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer Among Asian Patients - A Multi-center Chart Review
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 17 Jul 2024 Status changed from active, no longer recruiting to completed.
- 29 Apr 2024 Planned End Date changed from 31 May 2024 to 8 Oct 2024.
- 29 Apr 2024 Planned primary completion date changed from 31 May 2024 to 4 Jun 2024.